Carlos Martinez, MPH, Lauren Carruth, PhD, Hannah Janeway, MD, Lahra Smith, PhD, Katharine M. Donato, PhD, Carlos Piñones-Rivera, PhD, James Quesada, PhD, and Seth M. Holmes, MD, PhD
AMA J Ethics. 2022;E275-282. doi:
10.1001/amajethics.2022.275.
Denisse Rojas Marquez, MD, MPP and Hazel Lever, MD, MPH
“Very important persons” care contributes to multitiered, racially segregated health service delivery streams that influence clinicians’ conceptions of what patients deserve from them.
AMA J Ethics. 2023;25(1):E66-71. doi:
10.1001/amajethics.2023.66.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.
This case illustrates how emergency physicians find themselves with an empty toolbox and must compromise to meet their responsibilities to patients and themselves.
A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.